接受单纯冠状动脉旁路移植术的左主干病变与非左主干病变患者的临床事件发生率:欧洲DuraGraft注册研究结果
该研究为欧洲多中心DuraGraft注册研究的亚组分析,纳入接受单纯冠状动脉旁路移植术的患者,比较左主干冠状动脉疾病(LMCAD)与非LMCAD患者1年临床事件率。结果显示LMCAD患者主要不良心脏事件(MACE)发生率更高(8.2% vs 5.1%,P=0.002),但卒中发生率更低(1.0% vs 2.4%,P=0.011);倾向性评分匹配后MACE差异仍显著(8.0% vs 5.2%,P=0.015)。结论认为LMCAD是单纯CABG术后MACE的独立危险因素,而卒中风险较低。
要点
- LMCAD患者1年MACE发生率高于非LMCAD患者(8.2% vs 5.1%,P=0.002)。
- 倾向性评分匹配后LMCAD组MACE仍较高(8.0% vs 5.2%,P=0.015)。
- LMCAD组卒中发生率低于非LMCAD组(1.0% vs 2.4%,P=0.011)。
核心结论
- 在该大型注册研究中,LMCAD被证明是单纯CABG术后MACE的独立危险因素。
- 相反,LMCAD患者的卒中风险较低。
研究设计与样本
- 研究为欧洲多中心DuraGraft注册研究的亚组分析,纳入接受单纯CABG的患者。
- 主要终点为1年主要不良心脏事件(MACE),定义为死亡、心肌梗死或再次血运重建的复合终点。
- 次要终点为主要不良心脑血管事件(MACCE),定义为MACE加卒中。
- 采用倾向性评分匹配以平衡基线特征差异。
- 临床试验注册号:ClinicalTrials.gov NCT02922088。
主要发现
- LMCAD存在于1033例(41.2%)患者,非LMCAD为1477例(58.8%)。
- 1年时LMCAD组MACE发生率高于非LMCAD组(8.2% vs 5.1%,P=0.002), driven by higher rates of death(5.4% vs 3.4%,P=0.016)、MI(3.0% vs 1.3%,P=0.002)及数值上更高的RR(2.8% vs 1.8%,P=0.13)。
- MACCE发生率LMCAD组为8.8% vs 非LMCAD组6.6%,P=0.043;卒中发生率分别为1.0% vs 2.4%,P=0.011。
- 倾向性评分匹配后,LMCAD组与非LMCAD组MACE发生率为8.0% vs 5.2%,P=0.015。
- 匹配后LMCAD组与非LMCAD组死亡率为5.1% vs 3.7%,P=0.10;MI为3.0% vs 1.4%,P=0.020;RR为2.7% vs 1.6%,P=0.090;卒中为1.0% vs 2.4%,P=0.017;MACCE为8.5% vs 6.7%,P=0.12。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Left main coronary artery disease (LMCAD) is considered an independent risk factor for clinical events after coronary artery bypass grafting (CABG). We have conducted a subgroup analysis of the multicentre European DuraGraft Registry to investigate clinical event rates at 1 year in patients with and without LMCAD undergoing isolated CABG in contemporary practice. METHODS: Patients undergoing isolated CABG were selected. The primary end point was the incidence of a major adverse cardiac event (MACE) defined as the composite of death, myocardial infarction (MI) or repeat revascularization (RR) at 1 year. The secondary end point was major adverse cardiac and cerebrovascular events (MACCE) defined as MACE plus stroke. Propensity score matching was performed to balance for differences in baseline characteristics. RESULTS: LMCAD was present in 1033 (41.2%) and absent in 1477 (58.8%) patients. At 1 year, the MACE rate was higher for LMCAD patients (8.2% vs 5.1%, P = 0.002) driven by higher rates of death (5.4% vs 3.4%, P = 0.016), MI (3.0% vs 1.3%, P = 0.002) and numerically higher rates of RR (2.8% vs 1.8%, P = 0.13). The incidence of MACCE was 8.8% vs 6.6%, P = 0.043, with a stroke rate of 1.0% and 2.4%, P = 0.011, for the LMCAD and non-LMCAD groups, respectively. After propensity score matching, the MACE rate was 8.0% vs 5.2%, P = 0.015. The incidence of death was 5.1% vs 3.7%, P = 0.10, MI 3.0% vs 1.4%, P = 0.020, and RR was 2.7% vs 1.6%, P = 0.090, for the LMCAD and non-LMCAD groups, respectively. Less strokes occurred in LMCAD patients (1.0% vs 2.4%, P = 0.017). The MACCE rate was not different, 8.5% vs 6.7%, P = 0.12. CONCLUSIONS: In this large registry, LMCAD was demonstrated to be an independent risk factor for MACE after isolated CABG. Conversely, the risk of stroke was lower in LMCAD patients. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT02922088.
引用
- Caliskan E, Misfeld M, Sandner S, et al. Clinical event rate in patients with and without left main disease undergoing isolated coronary artery bypass grafting: results from the European DuraGraft Registry. Eur J Cardiothorac Surg. 2022. PMID: 35929787. doi:10.1093/ejcts/ezac403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。